Immune Checkpoint Inhibitors in the Treatment of Stage III NSCLC: A Primer for Managed Care Pharmacy

Join us for this engaging, clinic-focused symposium on the pharmacist’s role in leveraging checkpoint inhibitors for optimal care of patients with unresectable stage III NSCLC. Interact with your colleagues and gain expert perspectives from Ali McBride, PharmD, MS, BCOP; Sandra Cuellar, PharmD, BCOP; and Mark M. Awad, MD, PhD.


6:00 AM - 6:30 AM: Breakfast and Registration

6:30 AM - 6:40 AM: Welcome and Introduction                                          

6:40 AM - 7:00 AM: Background and Rationale for Immune Checkpoint Inhibitors in Unresectable Stage III NSCLC Ali McBride, PharmD, MS, BCOP (Program Director)

7:00 AM - 7:20 AM: Optimal Integration of Checkpoint Inhibitors Into the Management of Unresectable Stage III NSCLC Mark Awad, MD, PhD

7:20 AM - 7:40 AM: Strategies to Identify and Manage Immune-Mediated Adverse Events  Sandra Cuellar, PharmD, BCOP

7:40 AM - 8:00 AM: Panel Discussion and Audience Question and Answer Session: Clinical Challenges in Applying New Evidence to Practice in Early-Stage NSCLC


Date / Time
Event Details
6:00 AM


Program Director
Ali McBride, PharmD, MS, BCOP

Clinical Coordinator Hematology/Oncology
The University of Arizona Cancer Center
Tucson, Arizona

Mark Awad, MD, PhD

Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Sandra Cuellar, PharmD, BCOP

Clinical Pharmacist, Outpatient Medical Oncology and Hematology
Clinical Assistant Professor, Pharmacy Practice
Director, Oncology Residency
College of Pharmacy
The University of Illinois at Chicago
Chicago, Illinois


Goal Statement
The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with stage III non-small-cell lung cancer.

Target Audience
This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

  • Review evidence-based strategies for the management of stage III NSCLC, considering systemic and local therapeutic modalities
  • Discuss the biologic rationale for using immune checkpoint inhibitors in early-stage cancers
  • Develop management strategies to address immune-mediated adverse events in patients receiving checkpoint inhibitors
  • Educate patients about the benefits and risks of using immune checkpoint inhibitor therapy and provide preventive strategies to reduce or ameliorate these toxicities
  • Explain the role of the oncology pharmacist in optimizing the use of checkpoint inhibitor therapy for unresectable stage III NSCLC and opportunities to advance oncology pharmacy services
  • Address challenging questions regarding the management of unresectable stage III NSCLC and discuss ways the managed care pharmacist can aid in the implementation of clinical pathways to deliver quality care


Pharmacist Continuing Education

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-006-L01-P.

Type of Activity: Application

Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.